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TRANSPLANTATION OF THE LIVER 
FOR METASTATIC ENDOCRINE TUMORS 
OF THE INTESTINE AND PANCREAS 
Leonard Makowka, M.D., PH.D., Andreas G. Tzakis, M.D., Vincenzo Mazzaferro, M.D., 
Lewis Teperman, M.D., A. Jake Demetris, M.D., Shunzaburo Iwatsuki, M.D., F.A.C.S., 
and Thomas E. Starzl, M.D., PH.D., F.A.C.S., Pittsburgh, Pennsylvania 
In the Pittsburgh series of 7,000 orthotopic liver 
transplants (OLTx),Jrom January 7987 to July 1987, 
the indication for transplantation in five patients con-
sisted of unresectable hepatic metastases arising from 
endocrine tumors of gastrointestinal origin: glucago-
noma, two /Jatients; carcinoid, two, and gastrinoma, 
one patient, Three patients underwent resection of the 
primary tumor (two distal pancreatectomies and one 
ileal resection) at the time of the hepatic transplanta-
tion. All patients underwent extensive nodal dissection. 
Three of the five patients are alive with no evidence of 
residual disease after a median follow-up study of 72 
months. Hepatic transplantation broadens the concept 
of radical excision of tumor and may be considered as a 
potential therapeutic approach for some highly selected 
instances of lmresectable hepatic metastases arising 
from endocrine tumors of the intestine and pancreas. 
ENDROCRINE TUMORS of the intestine and pan-
creas are rare. In a large review of gastroin-
testinal neoplasms conducted at autopsy, the in-
cidence of these tumors was 1.5 per cent (1). The 
main histologic types consisted of carcinoids 
(greater than 90 per cent), insulinomas and gas-
trinomas (2, 3). 
The diagnosis of these tumors is quite com-
monly delayed and, thus, often associated with 
metastatic disease; the liver is the most commonly 
involved metastatic site (2). Because of the slow 
growth and less aggressive biologic nature of 
these tumors and because of their decreased ten-
dency to metastasize to other organs besides the 
liver, hepatic resection should always be consid-
ered to achieve, at least, palliation of symptoms 
and to prolong survival time (4). In theory, 95 per 
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cent of the involved liver should be removed to 
achieve such results. 
In those patients in whom this type of subtotal 
hepatic resection is impossible (for example, bi-
lateral disease or large central lesions), antihor-
monal therapy (5), cytotoxic chemotherapy (6) 
and ligation of the hepatic artery (7) have been 
attempted. These methods have provided poor 
long term control and palliation of the disease. In 
this report, we describe oUf experience with or-
thotopic liver transplantation (OL Tx) in five 
patients with un resectable hepatic metastases 
originating from endocrine tumors of. the gastro-
intestinal tract. The selection criteria for OL Tx, 
as well as a comparison with other conventional 
nonsurgical approaches to this problem, are pre-
sented. 
PATIENTS AND METHODS 
We have recently reviewed the records of the 
first 1,000 patients who underwent OLTx under 
immunosuppression with cyclosporine at the 
University of Pittsburgh from January 1981 to 
July 1987 (8). Five of these patients had histo-
logically proved endocrine tumors of gastrointes-
tinal origin with metastases to the liver. The 
clinical characteristics and histologic diagnoses 
are summarized in Table I. 
In all but one of these patients (No.1), the 
diagnosis of metastatic endocrine tumor was es-
tablished before transplantation. Patient No. 1 
underwent OL Tx for a presumed diagnosis of 
hepatocellular carcinoma, which was reclassified 
as metastatic glucagonoma 27 months later, after 
re-examination of the histologic slides. The de-
finitive diagnosis was established in all patients 
after a complete immunoperoxidase work-up 
study for enolase, glucagon, chromogranin, so-
matostatin and insulin on samples of tumor taken 
from the removed native liver, resection margins, 
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lymph nodes and, whenever present, from the an incomplete cycle of radiotherapy (interrupted 
primary tumor. Electron microscopic evaluation because of severe radiation enteritis), followed by 
was also performed to confirm the ultrastructural ten cycles of 5-fluorouracil given orally. Serial 
characteristics of the cells. monitoring of blood levels of the specific hor-
RESULTS 
The demographics of the five patients studied 
are presented in Table I. The ileum was the 
primary site of origin for the two metastatic car-
cinoid lesions, while the two glucagonomas and 
the one gastrinoma originated in the pancreas. 
Four of the five patients had syncronous me-
tastases, and three (Patient Nos. 3, 4 and 5) un-
derwent simultaneous resection of the primary 
tumor at the time of transplantation. This neces-
sitated two distal pancreatectomies and splenec-
tomies and one ileal resection. Patient No.1 had a 
final diagnosis of glucagonoma made almost two 
years after OLTx, and although his blood level of 
glucagon is presently suspicious at a fasting value 
of 157 picograms per milliliter (normal value of 
20 to 100· picograms per milliliter), the appear-
ance on computed tomographic scan of the pan-
creas has been stable for 34 months and, at the 
moment, there is no other evidence of disease (by 
nuclear magnetic resonance scan). The patient is 
in excellent health, and the possibility of under-
going a pancreatectomy is still under evaluation. 
All patients underwent extensive dissection of 
the lymph nodes of the hilar hepatic, periceliac 
and peri pancreatic areas as part of the transplant 
procedure. The presence of enlarged lymph nodes 
during the evaluation before transplantation was 
not considered to be a contraindication for OL Tx. 
The radical surgical procedure was considered to 
be complete when no tumor was grossly detecta-
ble in the surgical field at the end of the procedure 
and when the resection margins were free of dis-
ease for at least 0.5 centimeter from the tumor. 
Using these criteria, potentially curative resec-
tions were achieved in four patients; however, in 
Patient No.4, a focus of cholangiocarcinoma was 
detected at the resection margin of the bile duct. 
This patient died nine months after OL Tx of 
recurrent cholangiocarcinoma. Only one patient 
(No.4) with a full blown carcinoid syndrome 
underwent extensive preoperative chemotherapy. 
Two of the patients (Nos. 4 and 5) demonstrated 
symptoms classical for the hormone-producing 
cells of the tumor (6). No postoperative adjuvant 
treatment protocol was used. One patient (No.1) 
received Adriamycin® (doxorubicin hydrochlo-
ride) (100 milligrams per square meter for seven 
cycles) mainly for the original misdiagnosis of 
hepatocellular carcinoma. Patient No.4 received 
mones produced by each tumor has been used for 
follow-up study to detect possible recurrence of 
the disease. 
The more extensive surgical approach in these 
patients, especially Patient Nos. 3, 4 and 5, did 
not appreciably contribute to increased post-
operative morbidity when compared with con-
ventional OLTx. The one patient who died two 
months postoperatively had required retrans-
plantation for irreversible rejection, and the sec-
ond graft failed because of primary nonfunction. 
The other three patients are alive with no evi-
dence of disease at 34, 16 and seven months after 
OL Tx. In Patient No.4, levels of 5-hydroxy-
indoleacetic acid in the urine remained normal 
for the nine months that the patient was alive, and 
furthermore, there was no evidence of the carci-
noid component of the tumor at exploratory lap-
arotomy four months after OL Tx. There are no 
complaints of any endocrine-related symptoms, 
and in two of the three patients still alive, the 
levels of hormones are normal. 
DISCUSSION 
Classically, metastatic tumors of the liver have 
been considered to be a poor indication for 
OL Tx, and the results have been disappointing, 
even after sophisticated postoperative treatment, 
such as high-dose chemotherapy, irradiation of 
the total body and autologous bone marrow re-
constitution (9); however, these previously re-
ported instances of hepatic replacement have been 
for metastatic carcinoma of the breast, carcinoma 
of the colon and rectum, adenocarcinoma of un-
known origin, teratoma and melanoma (10-13). 
These types of tumors obviously have a much 
more biologically aggressive behavior, and there-
fore, the poor results with OL Tx and immuno-
suppression are not surprising. One instance of 
metastatic carcinoid without detailed description 
or follow-up study is cited in the Hannover series 
(12), and two instances of endocrine neoplasia 
were published recently in the Cambride-King's 
College experience (14); both patients are alive 
two and seven months after transplantation. 
The present report represents the first detailed 
evaluation of OL Tx for metastatic endocrine 
tumors. The biologically less aggressive nature of 
these tumors suggests a more favorable prognosis. 
In addition to the histopathologic criteria, con-
firmed by immunoperoxidase staining, several 
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TABLE I.-ORTHOTOPIC TRANSPLANTATION OF THE LIVER FOR METASTATIC ENDOCRINE TUMOR OF THE 
SMALL INTESTINE AND PANCREAS 
_________________ Patient No. ________________ _ 
Diagnosis on the liver 
specimen ............... Glucagonoma 
Age, yrs/Sex ............. 41/M 
Endocrine-related symptoms. No 
Preoperative hormone levels .. 
Primary tumor site ......... Pancreas? 
Per cent of metastatic hepatic 
involvement ............. >70 
Preoperative treatment ...... None 
Extrahepatic metastases at 
OLTx ................. Peri pancreatic 
lymph node 
Surgical treatment ......... OL Tx plus node 
dissection 
Radical surgical procedure, 
potential for cure ........ Yes 
Postoperative treatment ... .. Adriamycin® 
Recurrence .............. . 
Survival ................. . 
No 
Alive 34 mos., 
disease 
free(?)j 
glucagon, 
157 pgm./ml.jt 
pancreas 
without 
changes by 
NMRandCT 
scan for 34 mos. 
2 
Carcinoid 
52/F 
No 
Ileum, 
appendectomy 
>80 
None 
Peri pancreatic 
lymph nodes 
OL Tx plus node 
dissection 
Yes 
Died 2 mos. post-
operationj ir-
reversible 
rejection, t st 
graft and 
primary non-
function 2nd 
graft 
3 
Glucagonoma 
41/F 
Partial, glossitis 
Glucagon, 300 
pgm./ml. 
Pancreas 
80 
None 
No 
OL Tx plus distal 
pancreatectomy, 
splenectomy plus 
node dissection 
Yes 
No 
No 
Alive 16 mos., 
disease freej 
glucagon, 21 
pgm./ml. 
4 
Carcinoid plus 
cholangio-
carcinoma 
39/M 
Yes, full syndrome 
5HIAA, 217' 
mgm./24 hrs. 
Ileum 
70 
Chemotherapy for 
20 yrs. 
No 
OL Tx plus ileal 
resection 
5* 
Gastrinoma 
45/M 
Yes, severe 
gastric ulcers 
Pancreas 
>75 
None 
No 
OL Tx plus distal 
pancreatec-
tomy, splenec-
tomy plus node 
dissection 
No, focus of Yes 
cholangiocarcinoma 
at the bile duct 
margin 
Radiotherapy plus 
5FU 
No, carcinoidj yes, 
cholangiocarcinoma 
Died 9 mos., 
recurrence of 
cholangiocarcinomaj 
5HIAA, normal* 
No 
No 
Alive 7 mos., 
disease freej 
gastrin, 36 
pgm./ml.l 
·As of June 1988, six months after the submis.ion of thi. report, this patient treated for metastatic gastrinom. had multiple metasta..,. of the lung and bone 
develop (eight months after h .. path: Iflln_I,lantation). He died two months later. Oi • ..,minaled metastatic gallrinoma was noted at autopsy (lungs, hone, liver, 
pancreas, duodenum, ,..,cal mesentery an« right adrrnal glllnd). The two nther lurvlvlng pal lent. (Nos. I lind 3) remain disease-free al 41 and 23 months after 
hepatic transplantation, respectively. 
tNormal glucagon fasting value, 20 to 100 pgm./ml. 
*Normal level of 5HIAA in urine, t to 7 mgm./24 hr. 
INormalleveJ of gastrin, less than 100 pgm./ml. 
5HIAA, 5-Hydroxyindoleacetic acid; OL Tx, orthotopic liver transplantation; 5FU, 5-fluorouracil; NMR, nuclear magnetic resonance, and CT, computed 
tomography. ' 
clinical factors point to the decreased aggressive-
ness of these tumors. In all five instances, the 
tumors occupied 70 per cent or greater of the 
hepatic parenchyma, but seriously decreased 
performance was present in only one patient (No. 
4), who was found to have an incidental cholan-
giocarcinoma at OL Tx. In all patients, the clini-
cal history suggested a very slow growing hepatic 
lesion with the median interval from the diagnosis 
to OLTx being 12 months (a range oftwo months 
to 18 years) . No extrahepatic dissemination, 
other than lymph nodes, could be determined. 
Only two of the patients demonstrated the well 
known symptoms related to hormone secretion by 
the tumor, and in these two patients, the 
symptoms were present for two (No.5) and 18 
(No.4) years. The clinical behavior evident for 
this series of tumors is similar to that previously 
reported (4, 6, 15). 
Generally, when considering the natural his-
tory of the spread of the tumor, the probability 
that a tumor arising in an organ drained exclu-
sively by the portal system will give rise to hepatic 
metastases without metastases elsewhere is much 
higher than in tumors drained by systemic circu-
lation, with a ratio of ten to one (1). Moreover, 
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intestinal-related endocrine neoplasia have an 
even greater proclivity for metastasizing to the 
liver (16), with minimal or absent extrahepatic 
spread. In the instance of carcinoids, origin from 
the small intestine or pancreas, or both, is corre-
lated with a better prognosis and longer survival 
time than for carcinoids arising in other primary 
sites (4). In most occurrences of advanced carci-
noid tumors metastatic to the liver, death results 
from cardiac or hepatic failure secondary to the 
tumor replacement, usually without extrahepatic 
spread. 
The primary tumor in all of the patients pre-
sented in this series of metastatic endocrine tu-
mors originated in the more biologically favorable 
location, that is, drained by the portal system. 
Surgical treatment has always been considered 
the primary and potentially curative approach to 
hepatic metastases from intestinal-related endo-
crine tumors (2, 17) . Hepatic transplantation 
broadens the concept of a radical approach in 
those situations in which a subtotal hepatic re-
section cannot eradicate the majority of the dis-
ease. Extensive nodal dissection was performed 
upon all of the patients in this series. It is 
important to note that this aggressive approach 
should and can successfully be extended to the 
simultaneous remova,l of the primary lesion. 
The results of the present series are extremely 
encouraging thus far, in terms of survival time, 
disease-free interval and control of endocrine-
related syndromes. One patient died early of 
causes entirely related to the transplant proce-
dure itself; one patient died of recurrence of cho-
langiocarcinoma, which was found incidentally at 
the time of OLTx for a carcinoid tumor. The 
prognosis of OL Tx for cholangiocarcinoma is 
known to be extremely poor (14, 18). It should be 
emphasized that this patient had no evidence of 
recurrence of carcinoid for nine months. Three of 
the five patients are alive with no apparent evi-
dence of residual disease. The immunosuppres-
sive protocol used in these patients, consisting of 
cyclosporine and steroids (19), has not as yet ap-
peared to influence the behavior and course of the 
tumor significantly, particularly, because there 
has been no proved recurrence. 
The follow-up study (seven to 34 months) is 
still too short for these tumors to express their ul-
timate natural history, but the over-all results 
obtained to date are certainy encouraging. 
Moreover, our results for this disease compare 
favorably with other reported approaches to 
management. In patients treated with chemo-
therapy, the mean five year survival rate for un-
resectable metastatic gastrinoma is about 20 per 
cent (20), whereas the median survival time for 
carcinoid tumors originating in the small intes-
tine and pancreas with unresectable hepatic in-
volvement ranges from 21 to 29 months (21). The 
mean response with hepatic arterial ligation for 
metastatic carcinoid is only five months (8, 18). 
Although postoperative adjuvant treatment 
was not actually evaluated in the group of pa-
tients we studied, there is some suggestion from 
the two patients in the series who did receive such 
treatment that this approach may be beneficial 
and certainly warrants further study. Blood levels 
of tumor-related hormones can be used postop-
eratively to study recurrence of tumor, and the 
rapid decline of the levels of these hormones after 
OLTx can be considered to be an indirect index 
of successful resection (fable 1). 
In conclusion, OL Tx appears to be a thera-
peutic approach, which should be considered for a 
limited number of highly selected patients with 
unresectable metastatic hepatic disease originat-
ing from endocrine tumors of the small intestine 
and pancreas. With careful selection criteria for 
patients and with careful adherence to the prin-
ciples of surgical oncology, OL Tx can success-
fully control this disease and its associated endo-
crine syndromes for prolonged periods. 
SUMMARY 
Five patients who underwent OL Tx for unre-
sectable hepatic metastases originating from gas-
trointestinal endocrine tumors are presented. 
Careful selection criteria for patients, the unique 
biologic behavior of these tumors and strict ad-
herence to the principles of surgical oncology 
have resulted in extremely encouraging results. 
Four of the five patients are alive with no appar-
ent evidence of residual disease after a median 
follow-up study of 12 months. Three patients 
have maintained normal levels of tumor-related 
hormones, and none complain of any endocrine-
related symptoms. Hepatic transplantation con-
ceptually broadens the principles of radical onco-
logic surgery in selected instances of otherwise 
unresectable metastatic hepatic involvement from 
endocrine tumors arising in the intestine and 
pancreas. 
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